Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Liu X, Clemens DL, Lee BY, Aguirre R, Horwitz MA, Zhou ZH. Structure, identification and characterization of the RibD-enolase complex in Francisella. Protein Cell. 2025[...]
Mull HJ, Golenbock SW, Basnet Thapa D, Shin MH, Harvey KL, Lamkin RP, Strymish J, Branch-Elliman W. Cardiac Implantable Device Infection Surveillance Algorithm. JAMA Netw[...]
Wallace HL, Wight J, Rzeszutek GJ, Jafri MS, Baz M, Dowding B, Flamand L, Hobman T, Jean F, Joy JB, Lang AS, MacParland S, McCormick[...]